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Background: Epidermal growth factor receptor (EGFR) mutations
in non-small cell lung cancer (NSCLC) predict response to tyrosine
kinase inhibitors. Mutations occur more commonly in never smokers
and East Asians, but there are conflicting reports on the frequency of
EGFR mutations in tumors from African Americans.
Methods: Tumors from 67 African American and 77 white partic-
ipants in previous case-control studies of lung cancer were selected
to determine EGFR mutational status. Mutation analysis was per-
formed using the Sequenom mass array analyzer (Sequenom, San
Diego, CA).
Results: Overall, 13.9% of the study population carried an EGFR
mutation. EGFR mutations occurred in 11.9% of tumors from
African Americans compared with 15.6% in whites (p  0.53). All
mutations found in African Americans were deletions in exon 19.
The majority of mutations were found in nonsmokers among both
African Americans (7/8) and whites (8/12).
Conclusion: These results indicate that African Americans with
NSCLC harbor somatic EGFR mutations at a frequency similar to
whites with NSCLC. Thus, clinicians should not use race as a
clinical decision parameter for the use of EGFR-tyrosine kinase
inhibitors.
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Epidermal growth factor receptor (EGFR) is a tyrosinekinase involved in cell signaling, and somatic mutations in
patients with non-small cell lung cancer (NSCLC) are predictive
of response to EGFR tyrosine kinase inhibitors (TKIs), with 70
to 80% of patients deriving substantial benefit from this
therapy.1,2 Several studies have documented that most pa-
tients responding to EGFR-TKIs have mutations in the ATP-
binding regions of the gene.3–6 More than 90% of these
mutations involve either a deletion in exon 19 or a point
mutation (L858R) in exon 21.7
EGFR mutations occur predominantly in never smok-
ers and are more common in patients with adenocarcinoma,
East Asian ethnicity, and in women.3–6 Less is known about
the mutation frequency in other ethnic groups, and studies in
African American patients have yielded conflicting results.
Two studies reported that the EGFR mutation frequency in
African Americans was about 2% compared with the reported
frequency of 15 to 20% in whites.7,8 In contrast, Riely et al.9
reported 42.9% of the 14 tumors, which they studied from
African Americans-harbored EGFR mutations.
The decision to offer EGFR testing is usually deter-
mined by whether the patient matches the clinical profile of
an individual who would be likely to harbor a mutation. The
purpose of this investigation was to examine the frequency
and characteristics of EGFR mutations in a cohort of African
Americans and whites with NSCLC to determine whether a
difference in EGFR mutation frequency exists by race.
METHODS
Tumors from participants in previous population-based
case-control studies of lung cancer from 1985 to 2008
(A.G.S.) who had consented to allow their tissue to be used
for research purposes were selected to determine EGFR
mutation status. These subjects had detailed demographic and
information (age, race, smoking status, pack years of smok-
ing) available from previous interviews, and clinical infor-
mation (histology, stage, and grade) available from the Met-
ropolitan Detroit Cancer Surveillance System, part of the
national Surveillance, Epidemiology, and End Results pro-
gram. Never smokers, light smokers, and individuals with
adenocarcinoma were oversampled, and cases were fre-
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quency matched by race on sex, smoking status, and histol-
ogy. Never smokers were defined as individuals smoking
fewer than 100 cigarettes in their lifetime.
We used the OncoCarta Panel V1.0 developed by
Sequenom, which examined 238 mutations in 19 different
oncogenes. This method was chosen because of its sensitivity
(as low as 10% mutant allele frequency) and high throughput.
For the purposes of this analysis, we focused on 43 known
mutations in EGFR included in this panel. Mutation analysis
was performed using the mass-spectroscopy based Mass-
Array device developed by Sequenom. DNA was extracted
from formalin-fixed paraffin embedded tumors using a stan-
dard kit (Qiagene, 51306). Briefly, an initial polymerase
chain reaction is performed to amplify a small region, which
included the potential point mutation site. Next, a 10-base
DNA oligonucleotide primer binds immediately upstream of
the mutation site and is extended by one base into the
potential mutation site. The primers are subsequently sepa-
rated on a matrix-assisted laser desorption/ionization time of
flight mass spectrometer, which is able to quantitatively
discern the specific nucleotide that was extended.
Differences by race and mutation status were assessed
for categorical variables using p values from 2 tests or
Fisher’s exact test when expected cell frequency was less
than 5. Comparisons were made using t tests for continuous
variables. Differences were considered to be statistically
significant at alpha0.05. All analyses were performed using
SPSS Version 18.
RESULTS
Tumor samples were obtained from 67 African Amer-
ican and 77 white patients with NSCLC. The demographic
characteristics of the patients are listed in Table 1. At the time
of diagnosis, African Americans were older compared with
whites (p  0.03), but other key parameters did not differ
between racial groups. EGFR mutations were found in 13.9%
of tumors from the total population (Table 2). Fifteen muta-
tions occurred in never smokers with an additional two
mutations found in patients with a smoking history of only
one pack year. The majority of mutations were found in
adenocarcinomas (n  18), with two squamous cell carcino-
mas also harboring a mutation (p  0.10). The mutation
frequency in never smokers was 47% (data not shown).
EGFR mutations did not differ by race with a frequency of
11.9% in African Americans and 15.6% in whites (p 0.53).
Figure 1 illustrates the relationship between smoking status,
race, and frequency of different mutation types. Mutations
were found in 7 of 11 tumors from African American never
smokers (63.6%) and 8 of 21 (38.1%) tumors from white
never smokers (p  0.27). All eight mutations in African
Americans were exon 19 deletions, whereas mutations in
whites included exon 19 deletions (n 7, 58.3%), the L858R
point mutation in exon 21 (n  3, 25%), and 2 exon 18
mutations, E709A and G719S (16.7%). There was no statis-
tically significant difference between the types of mutations
carried by race (p  0.17, data not shown).
DISCUSSION
Lung cancer remains the leading cause of cancer-
related death in the United States with estimates of more than
150,000 deaths in 2009, and an overall 5-year survival of
16%.10 The majority of these cases are NSCLC. EGFR-TKIs
have extended survival in some NSCLC patients. Clinical and
biological studies have determined that TKI-responders are
primarily those with EGFR mutations.3–6 The recently com-
pleted phase III IPASS trial reported that the hazard ratio for
TABLE 2. Patient Characteristics by EGFR Mutation Status
EGFR Mutations
(n  20)
Wild Type
(n  124)
pN (%) N (%)
Ethnicity 0.53
White 12 (60.0) 65 (52.4)
African American 8 (40.0) 59 (47.6)
Mean age at diagnosis 63.8 56.4 0.02
Sex 0.33
Male 4 (20.0) 38 (30.6)
Female 16 (80.0) 86 (69.4)
Smoking status 0.001
Never 15 (75.0) 17 (13.7)
Ever 5 (25.0) 107 (86.3)
Histology 0.10
Adenocarcinoma 18 (90.0) 87 (70.2)
Other NSCLC 2 (10.0) 37 (29.8)
Stage at diagnosis 0.18
I 3 (15.0) 47 (37.9)
II 10 (50.0) 50 (40.3)
III 5 (25.0) 23 (18.5)
Missing 2 (10.0) 4 (3.2)
EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer.
TABLE 1. Demographic Characteristics of the Study
Population, by Race
Whites
(n  77)
African Americans
(n  67)
pN (%) N (%)
Mean age at diagnosis 55.2 60.0 0.03
Sex 0.20
Male 19 (24.7) 23 (34.3)
Female 58 (73.3) 44 (65.6)
Smoking status 0.12
Never 21 (27.3) 11 (16.4)
Ever 56 (72.7) 56 (83.6)
Histology 0.75
Adenocarcinoma 57 (74.0) 48 (71.6)
Other NSCLC 20 (26.0) 19 (28.4)
Stage at diagnosis 0.47
I 30 (39.0) 20 (29.9)
II 31 (40.3) 29 (43.3)
III 13 (16.9) 15 (22.4)
Missing 3 (3.8) 3 (4.4)
NSCLC, non-small cell lung cancer.
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progression or death was 0.48 in patients with EGFR muta-
tions treated with gefitinib compared with those treated with
carboplatin-paclitaxel (p  0.001).1 The 12-month progres-
sion-free survival rate was significantly higher with gefitinib
in that study of nonsmokers or former light smokers with
adenocarcinoma (24.9% in the gefitinib group versus 6.7%
for carboplatin-paclitaxel).1 This study illustrates the clinical
relevance of the EGFR mutational status for therapeutic
decision making in patients with advanced NSCLC.
Contrary to recent reports, we observed no statistically
significant difference in EGFR mutation frequency in tumor
samples from whites and African Americans, in the largest
study of African Americans to date. Studies reporting the
frequency of EGFR mutations, including the present report,
must be interpreted with caution because the composition of
the patient population may influence the results. EGFR mu-
tations occur predominantly, although not exclusively, in
never smokers. Pao et al.5 found EGFRmutations in only four
of 481 samples from smokers compared with seven mutations
in 15 tumors from never smokers. This mutation rate is
similar to our observation of 15 mutations in 32 never
smokers. Because 10% of patients with NSCLC are never
smokers, EGFR mutation rates will be low unless the study
population is enriched with these individuals.
The mutation frequency in whites in our study is similar
to other reports in white populations.7–9 In African Ameri-
cans, Riely et al.9 studied 14 tumors (eight were never
smokers) and found EGFR mutations in six patients, similar
to our findings that approximately 2/3 of African American
never smokers harbored a mutation in EGFR. It is unclear
why both Yang et al.7 and Leidner et al.8 reported finding
only a single EGFR mutation after studying 41 and 53
African Americans with NSCLC, respectively, but it may
have been because of the inclusion of relatively few never
smokers in these investigations, or chance.
EGFR mutations of importance in NSCLC seem to be
confined to the first 4 exons(18–21) of the ATP-binding
region of the tyrosine kinase receptor. In our white subjects,
exon 19 mutations accounted for two thirds of EGFR muta-
tions, yet all the mutations observed in African Americans
were deletions in exon 19. Larger studies are needed to
determine whether significant differences exist in mutation
type between African Americans and whites or whether this
is an anomaly related to the sample size or some unique
characteristic of our study cohort.
Determination of mutation type may have clinical rel-
evance because some studies have demonstrated that treat-
ment response varies with mutation type. Riely et al.9 re-
ported that patients with exon 19 deletions treated with TKIs
had a median survival of 34 months compared with only 8
months in those with the exon 21 L858R point mutation.
Jackman et al.11 found that length of survival was more than
doubled (38 months versus 17 months) for patients with exon
19 deletions. In addition, a study examining the association
between EGFR mutations and outcome of erlotinib treatment
found a higher probability of response associated with the
exon 19 deletion (p  0.001).12 These findings have not been
confirmed in two studies involving Japanese patients, in
FIGURE 1. The number of EGFR
mutations by race and smoking
status.
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which no significant difference was noted in progression-free
survival based on EGFR mutation type.13,14 In conclusion,
this study suggests that EGFR mutations occur as frequently
in African Americans as in whites. Thus, clinicians should
not use race as a clinical decision parameter for the use of
EGFR-TKIs.
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